Samuel Backenroth
Keine laufenden Positionen mehr
Vermögen: 14 400 $ am 30.04.2024
Karriereverlauf von Samuel Backenroth
Ehemalige bekannte Positionen von Samuel Backenroth
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
NEUBASE THERAPEUTICS, INC. | Finanzdirektor/CFO | 01.07.2019 | 30.09.2021 |
Unternehmenssekretär | 01.07.2019 | 30.09.2021 | |
Treasurer | 01.07.2019 | 30.09.2021 | |
Neubase Therapeutics, Inc. /Old/
Neubase Therapeutics, Inc. /Old/ Pharmaceuticals: MajorHealth Technology Neubase Therapeutics, Inc. develops peptide-nucleic acid antisense oligonucleotide platform. Its platform address repeat expansion disorders, with an initial focus on huntington’s disease and myotonic dystrophy, as well as other dominant genetic disorders. The company was founded by Dietrich A. Stephan and is headquartered in Pittsburgh, PA. | Finanzdirektor/CFO | 12.07.2019 | 01.01.2021 |
Unternehmenssekretär | 12.07.2019 | 01.01.2021 | |
Treasurer | 12.07.2019 | 01.01.2021 | |
Ohr Pharmaceutical, Inc.
Ohr Pharmaceutical, Inc. Pharmaceuticals: MajorHealth Technology Ohr Pharmaceutical, Inc. engages in the development of novel therapeutics and delivery technologies for the treatment of ocular disease. Its product portfolio includes squalamine and SKS sustained release technology. The company was founded by Irach B. Taraporewala in 2008 and is headquartered in New York, NY. | Comptroller/Controller/Auditor | 06.06.2012 | 01.01.2019 |
Finanzdirektor/CFO | 12.04.2010 | 01.01.2019 | |
Public Communications Contact | 12.04.2010 | 01.01.2019 | |
Unternehmenssekretär | 06.06.2012 | 01.01.2019 | |
NOTABLE LABS, LTD. | Finanzdirektor/CFO | 05.10.2021 | - |
Orphion Therapeutics, Inc.
Orphion Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Orphion Therapeutics, Inc. develops novel gene therapies for the treatment of genetic disorders. The private company is based in Great Neck, NY. The company was founded by Samuel I. Backenroth. The CEO is Jason Scott Slakter. | Gründer | - | - |
DepYmed, Inc.
DepYmed, Inc. BiotechnologyHealth Technology DepYmed , Inc. is a cancer and rare disease therapeutic development company. The company is headquartered in Farmingdale, NY. | Direktor/Vorstandsmitglied | 01.01.2014 | - |
Gründer | - | - |
Ausbildung von Samuel Backenroth
Touro College | Undergraduate Degree |
Statistik
International
Vereinigte Staaten | 7 |
Israel | 2 |
Operativ
Director of Finance/CFO | 5 |
Corporate Secretary | 3 |
Founder | 2 |
Sektoral
Health Technology | 7 |
Consumer Services | 2 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
Börsennotierte Unternehmen | 1 |
---|---|
NEUBASE THERAPEUTICS, INC. | Health Technology |
Private Unternehmen | 5 |
---|---|
Ohr Pharmaceutical, Inc.
Ohr Pharmaceutical, Inc. Pharmaceuticals: MajorHealth Technology Ohr Pharmaceutical, Inc. engages in the development of novel therapeutics and delivery technologies for the treatment of ocular disease. Its product portfolio includes squalamine and SKS sustained release technology. The company was founded by Irach B. Taraporewala in 2008 and is headquartered in New York, NY. | Health Technology |
DepYmed, Inc.
DepYmed, Inc. BiotechnologyHealth Technology DepYmed , Inc. is a cancer and rare disease therapeutic development company. The company is headquartered in Farmingdale, NY. | Health Technology |
Neubase Therapeutics, Inc. /Old/
Neubase Therapeutics, Inc. /Old/ Pharmaceuticals: MajorHealth Technology Neubase Therapeutics, Inc. develops peptide-nucleic acid antisense oligonucleotide platform. Its platform address repeat expansion disorders, with an initial focus on huntington’s disease and myotonic dystrophy, as well as other dominant genetic disorders. The company was founded by Dietrich A. Stephan and is headquartered in Pittsburgh, PA. | Health Technology |
Orphion Therapeutics, Inc.
Orphion Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Orphion Therapeutics, Inc. develops novel gene therapies for the treatment of genetic disorders. The private company is based in Great Neck, NY. The company was founded by Samuel I. Backenroth. The CEO is Jason Scott Slakter. | Health Technology |
Vascular Biogenics Ltd.
Vascular Biogenics Ltd. BiotechnologyHealth Technology Vascular Biogenics Ltd. is a clinical-stage biopharmaceutical company, which engages in the development of next-generation, targeted medicines for difficult-to-treat medical conditions. Its product candidates are built off of its platform technologies: Vascular Targeting System (VTS), a gene-based technology targeting newly formed blood vessels and Monocyte Targeting Technology (MTT), an antibody-based technology able to specifically inhibit monocyte migration for immune-inflammatory applications. The company was founded by Dror Harats and Jacob George on January 27, 2000 and is headquartered in Modi'in, Israel. | Health Technology |
- Börse
- Insiders
- Samuel Backenroth
- Erfahrung